NasdaqGM:PTGXBiotechs
Assessing Protagonist Therapeutics (PTGX) Valuation After Rusfertide NDA Filing And Rising Analyst Optimism
Protagonist Therapeutics (PTGX) is back in focus after filing a New Drug Application for rusfertide in polycythemia vera with partner Takeda, alongside fresh analyst enthusiasm and insider share sales for tax purposes.
See our latest analysis for Protagonist Therapeutics.
The stock’s recent 3.06% 1 day and 9.90% 90 day share price returns, alongside a very large 1 year total shareholder return of about 2.3x, suggest momentum building around the rusfertide filing and broader clinical story,...